IC
COGT icon

Innealta Capital’s Cogent Biosciences COGT Stock Holding History

Innealta Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-86
Closed -$725 – 474
2024
Q2 		$725 Buy
+86
New +$652 ﹤0.01% 1386

Other funds holding COGT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Innealta Capital's COGT Position: Q3 2024 in Review

Innealta Capital sold out of Cogent Biosciences (COGT) in Q3 2024, closing a stake of 86 shares — an estimated $725 sold.

Innealta Capital first reported a position in COGT in Q2 2024 and held it in 1 quarter. The position peaked at $725 in Q2 2024. 161 funds tracked by Wall St. Rank hold COGT as of Q3 2024.

  • Innealta Capital reported no remaining Cogent Biosciences position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 86 Cogent Biosciences shares in Q3 2024, an estimated $725.
  • Innealta Capital first reported a position in Cogent Biosciences in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Cogent Biosciences position peaked at $725 in Q2 2024.
  • 161 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.